ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      58,742.28
      1.47%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Kazia Therapeutics Ltd (KZIA)

      7. Kazia Therapeutics Ltd (KZIA) News

      KZIA

      Kazia Therapeutics (KZIA)

      Kazia Therapeutics Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:KZIA
      DateTimeSourceHeadlineSymbolCompany
      07/06/20234:15PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      07/06/20237:00AMPR Newswire (US)KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPYNASDAQ:KZIAKazia Therapeutics Ltd
      06/26/20237:01AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      06/08/20237:00AMPR Newswire (US)KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMANASDAQ:KZIAKazia Therapeutics Ltd
      06/05/20237:36AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      05/25/20237:01AMPR Newswire (US)KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOTNASDAQ:KZIAKazia Therapeutics Ltd
      05/01/20237:15AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      04/14/20237:50AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      04/14/20237:01AMPR Newswire (US)KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTNASDAQ:KZIAKazia Therapeutics Ltd
      04/04/20237:33AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      04/04/20237:00AMPR Newswire (US)KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
      03/09/20237:33AMEdgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:KZIAKazia Therapeutics Ltd
      02/24/20234:33PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      02/24/20237:36AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      01/20/20237:59AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      01/17/20238:26AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      01/16/20237:01AMPR Newswire (US)KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMSNASDAQ:KZIAKazia Therapeutics Ltd
      12/15/20227:45AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      12/15/20227:01AMPR Newswire (US)KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILINGNASDAQ:KZIAKazia Therapeutics Ltd
      12/12/20224:02PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      12/12/20227:01AMPR Newswire (US)KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATIONNASDAQ:KZIAKazia Therapeutics Ltd
      12/01/20224:14PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      12/01/20227:01AMPR Newswire (US)COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNALNASDAQ:KZIAKazia Therapeutics Ltd
      11/09/20227:00AMPR Newswire (US)KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
      11/03/20227:31AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      10/27/20227:22AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      10/27/20227:00AMPR Newswire (US)KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMANASDAQ:KZIAKazia Therapeutics Ltd
      10/14/20227:06AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      10/06/20228:00AMPR Newswire (US)PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLYNASDAQ:KZIAKazia Therapeutics Ltd
      09/15/20229:13AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
       Showing the most relevant articles for your search:NASDAQ:KZIA